Clinical uses of vitamin E.
Early administration of vitamin E to low birth weight (less than 1500 g) infants results in alleviation of the symptoms of retinopathy of prematurity and a lowered incidence of intraventricular hemorrhage. If vitamin E is given to children with cholestatic liver disease (orally or parenterally) before 3 years of age, neurological symptoms such as areflexia, ataxia, and sensory neuropathy are prevented or reversed. Restitution of neurological function is more limited in children ages 5-17 years even after prolonged therapy. Vitamin E is also useful in prevention of neuropathy and retinopathy associated with abetalipoproteinemia and cystic fibrosis. Blood levels of tocopherol are often low in subjects with hemolytic anemias. Administration of vitamin E to G-6-P-D-deficient subjects increased hemoglobin levels, and decreased the number of irreversibly sickled cells in sickle-cell anemia subjects. Most trials have indicated that administration of vitamin E for 6 months or more to subjects with intermittent claudication results in longer walking distance and improved blood flow. Vitamin E reduces platelet aggregation, platelet adhesion to collagen, and platelet thromboxane production. Prostacyclin production is generally enhanced. The significance of these effects to thrombotic diseases. Epidemiological studies have indicated that subjects with higher blood levels of vitamin E have lower risk of death from ischemic heart disease and cancer, a lower risk of breast cancer, and a lower incidence of infections.
D000293:Adolescent; D000328:Adult; D000743:Anemia, Hemolytic / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects; D001943:Breast Neoplasms / Q000097:blood; D002648:Child; D002675:Child, Preschool; D002780:Cholestasis, Intrahepatic / Q000188:drug therapy; D003327:Coronary Disease / Q000097:blood; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000097:blood; D006801:Humans; D007223:Infant; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D012164:Retinal Diseases / Q000517:prevention & control; D014810:Vitamin E / Q000097:blood / Q000627:therapeutic use*
D014810:Vitamin E